Preferences for public health insurance coverage of new anticancer drugs

A discrete choice experiment among non-small cell lung cancer patients in China

Bibliographic Data

ID15375994
AuthorsJingyi Meng (Nantong University, corresponding author), Feifei Yan (0009-0006-3229-499X, Nantong University), Maochun Chen (Nantong University), Yuchen Ding (0000-0002-6539-5213, Nantong University), Zhe Feng (0000-0001-6230-645X, Nantong University), Wenzhang Lu (0000-0002-2385-2260, Nantong University), Jinsong Geng (0000-0003-3389-9051, Nantong University)
Year2025
Volume25
Issue1
Pages164-164
Publication date2025-01-15
Open AccessYes
TypeARTICLE
VenueBMC Public Health (JOURNAL)
Journal identifiersISSN: 1471-2458 • E-ISSN: 1471-2458
PublisherBioMed Central (PUBLISHER • GB)
DOI10.1186/s12889-024-20951-6
PMID39815238
OpenAlexW4406402360
LanguageEN
Citations received1
References cited55

Health insurance policymakers need to consider the affordability, comparative survival benefits, comparative safety, and comparative patient-reported outcomes of new anticancer drugs. The findings also highlight the need to ensure affordability for older patients, low-income patients, and patients with advanced cancer

Actuarial science · Biostatistics · China · Economic growth · Environmental health · Health care · Health insurance · Lung cancer · Pathology · Public health · Economic and Financial Impacts of Cancer · Health Systems, Economic Evaluations, Quality of Life · Medicine · Patient-Provider Communication in Healthcare · Epidemiology · Internal Medicine · Oncology

Tools

Open DOIOpen Access